Jardiance

For UK healthcare professionals only

d e s n e c i l w o N

EMPOWERED BY YOU

POWERED BY

ll a c a t s e u q e r o t e Click her Now licensed in adults for the treatment of symptomatic chronic heart failure with 1 reduced ejection fraction Reference 1. JARDIANCE (empagliflozin) Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Click here for Prescribing information Great Britain

Click here for Prescribing information Northern Ireland

PC-GB-105714 Date of preparation October 2021

d e s n e c i l w o N

In the treatment of patients with HFrEF

EMPOWERED BY YOU POWERED BY JARDIANCE (empagliflozin) Proven efficacy

• JARDIANCE

demonstrated superiority in reducing the risk of CV death or HHF in patients on top of SoC vs. placebo with 25% RRR, 5.2% ARR (events occurred in 361 patients (19.4%) in the JARDIANCE group vs. 462 patients 2 (24.7%) in the placebo group (HR, 0.75; 95% CI, 0.65 to 0.86; p<0.001)) • J ARDIANCE reduced first and recurrent HHF by 30% RRR, 8.8% ARR vs. placebo (388 events and 553 events, respectively (HR, 0.70; 95% CI, 2 0.58 to 0.85; p<0.001)) • S lows kidney function decline vs placebo (JARDIANCE is not indicated for 2 the treatment of kidney disease)

ll a c a t s e u q e r o t e r e Click h

®

Well established safety profile in T2D

• Hypoglycaemia (when used with sulphonylurea or insulin) 1 and volume depletion are cited as very common • UTIs, GTIs, thirst, constipation, pruritis, rash, increased urination and 1 serum lipids increase are cited as common adverse events

Simple once daily 10mg dosing, no titration required • JARDIANCE can be used down to an eGFR of 20ml/min/1.73m² ¹

Consider adding JARDIANCE to your standard of care in HFrEF References 1. JARDIANCE (empagliflozin) Summary of Product Characteristics.

2. P acker M, Anker SD, Butler J, et al. N Engl J Med. 2020;383(15):1413-1424. (& Supplementary appendix)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Click here for Prescribing information Great Britain

Click here for Prescribing information Northern Ireland

1

PC-GB-105714 Date of preparation October 2021

1